EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Obesity on Systemic Treatment Outcomes in Metastatic Urological Malignancies

A Handke, M Silberg, C Orf, C Loeffelholz, P Bach iD, S Berg, F Roghmann, K H Tully iD

Obesity Science & Practice · 2026-06 · 12 (3)

DOI: 10.1002/osp4.70164 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity Science & Practice, online erschienen am 05.06.2026. Verfasst von A Handke und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Neurourology Marien Hospital Herne, Ruhr-University Bochum Bochum Germany. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Obesity increasingly influences treatment outcomes in urological malignancies (metastatic bladder cancer (BC), renal cell cancer (RCC), and prostate cancer (PC)). This study evaluated the impact of obesity on survival in patients with major metastatic urological cancers receiving systemic therapy. Materials and Methods Patients with metastatic BC, RCC, and PC treated at a high‐volume center from 2017 to 2025 were retrospectively analyzed. In total, 387 patients were included (BC: n = 166; RCC: n = 63; PC: n = 158) and stratified by the body mass index [BMI]. Overall survival was assessed using restricted mean survival time (RMST) at predefined landmarks (24 months for BC and RCC; 36 months for PC).

Results

Overall, 23.5% of the patients had obesity, with the highest prevalence in RCC (44.4%). In metastatic BC, obesity was not associated with differences in RMST at 24 months. In RCC, patients with obesity showed a numerical improvement in RMST and a significantly longer duration of systemic therapy. In contrast, patients with obesity with metastatic PC demonstrated significantly shorter RMST at 36 months than patients without obesity.

Conclusion

The prognostic impact of obesity differs across metastatic urological malignancies. While the present findings support an obesity paradox in RCC, obesity was associated with worse survival in metastatic PC but showed no impact on survival in BC. These results highlight the need for tumor‐specific biological interpretation of BMI‐related outcomes.

Schlagwörter

Stichwörter der Autor:innen

bladder cancerobesityoverall survivalprostate cancerrenal cell cancersystemic therapies

Autor:innen und Institutionen

  • Department of Urology and Neurourology Marien Hospital Herne, Ruhr-University Bochum Bochum Germany.

ORCID-Profile: P Bach, K H Tully

Zitieren

APA

Handke, A., Silberg, M., Orf, C., Loeffelholz, C., Bach, P., Berg, S., Roghmann, F., & Tully, K. H. (2026). Impact of Obesity on Systemic Treatment Outcomes in Metastatic Urological Malignancies. Obesity Science & Practice, 12(3). https://doi.org/10.1002/osp4.70164

Vancouver

Handke A, Silberg M, Orf C, Loeffelholz C, Bach P, Berg S, et al. Impact of Obesity on Systemic Treatment Outcomes in Metastatic Urological Malignancies. Obesity Science & Practice. 2026;12(3). doi:10.1002/osp4.70164

BibTeX
@article{Handke2026,
  author = {Handke, A and Silberg, M and Orf, C and Loeffelholz, C and Bach, P and Berg, S and Roghmann, F and Tully, K H},
  title = {Impact of Obesity on Systemic Treatment Outcomes in Metastatic Urological Malignancies},
  journal = {Obesity Science & Practice},
  year = {2026},
  volume = {12},
  number = {3},
  doi = {10.1002/osp4.70164}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche